WeightCare Tirzepatide Review

WeightCare gets several structural things right and one clinical thing wrong. Our research (August 8, 2026) found genuine pricing transparency attached to an eligibility floor that sits inside the normal weight range.

The Pricing Is Published, in Detail

Unusually for this market, WeightCare publishes actual multi-month figures:

• Monthly renewal: $499
• 3-month: $997 for 7.5 mg/week over 12 weeks — about $333/month
• 3-month high dose: $1,350 for up to 15 mg/week over 12 weeks — about $450/month
• 6-month high dose: $2,150 for up to 15 mg/week over 24 weeks — about $358/month

WeightCare does the per-month arithmetic itself rather than leaving buyers to work out that a $997 sticker is $333/month. It also states plainly that longer programs deliver "the best value per dose," which is true and verifiable from its own numbers.

Full Refund If You Are Not a Candidate

"If you are deemed a non-candidate for a particular WeightCare treatment by your assigned WeightCare physician, then you will be refunded in full." That is the right policy, and it is not universal. It means a patient who pays and is then declined is not out of pocket for a consultation they could not use.

Financing, Disclosed Honestly

WeightCare partners with Affirm for 3-month and 6-month programs, and discloses the terms including the uncomfortable part: "APR options range from 0% to 36%." Publishing a 36% ceiling rather than advertising only the 0% is honest. It also states clearly that "choosing Affirm is a payment option only. It does not affect your clinical eligibility" — separating the credit decision from the medical one.

The BMI 20 Problem

WeightCare offers 3-month microdosing plans for semaglutide and tirzepatide "if you're interested in weight management and have a BMI of 20+." A BMI of 20 is squarely within the normal healthy range. The FDA-approved indication begins at 30, or 27 with a weight-related condition. Prescribing a GLP-1 to someone at BMI 20 is not weight management in any clinical sense the approvals contemplate, and microdosing itself has no evidence base — sub-therapeutic doses were not what the trials studied. This is the same pattern we flagged at EllieMD, and the contrast with Setpoint Wellness, which publishes the actual approved thresholds, is stark.

Products and Logistics

The catalogue includes semaglutide (all doses), tirzepatide up to 7.5 mg, tirzepatide high doses, a tirzepatide spray, and semaglutide and tirzepatide microdosing. The spray, like other non-injectable formats we have reviewed, has no published absorption or dosing evidence. Prescriptions are filled by what WeightCare calls an "accredited US pharmacy," shipped in a small box with ice packs, arriving in 5-7 business days with tracking. WeightCare's compounding disclosure is correctly worded, noting that compounded drugs are "prepared by a state-licensed sterile compounding pharmacy partner" and "are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review." It also correctly distinguishes Zepbound and Wegovy as FDA-approved for weight loss from Ozempic and Mounjaro as approved for type 2 diabetes and prescribed off-label.

State Coverage Is Complicated

Coverage differs by program, which WeightCare publishes rather than hides:

• Monthly semaglutide, semaglutide microdose and monthly tirzepatide: all states except AK, HI, LA, MS
• Three-month semaglutide and tirzepatide: all except AK, AR, CA, HI, KY, LA, MS, MT, SC
• Three-month semaglutide microdosing: all except AK, AL, AR, CA, HI, KS, MI, MN, MS

Cancellation Friction

To cancel, WeightCare requires an email to help@joinweightcare.com with "CANCEL" in the subject line, after which an agent confirms. Its FAQ elsewhere points to a patient portal for cancellation steps. Requiring a specifically formatted email rather than a one-click in-account cancellation is friction, and friction in cancellation flows is rarely accidental.